New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 2, 2013
05:55 EDTGLW, GLW, GSK, GSK, PFE, PFE, BAYRY, BAYRY, LLY, LLY, SNY, SNY, MNTA, MNTA, ONXX, ONXX, AMGN, AMGN, MRK, MRK, CBST, CBST, BIIB, BIIB, SHPG, SHPGBoston Biotech Conferences to host a conference
BD Biotech Conference is being held in Boston on April 2-3.
News For GLW;BIIB;CBST;MRK;AMGN;ONXX;MNTA;SNY;LLY;BAYRY;PFE;GSK;SHPG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
December 5, 2014
10:05 EDTPFEBristol-Myers jumps 2% amid talk of potential Pfizer bid
Shares of Bristol-Myers (BMY) are up in early trading amid chatter of a potential takeover bid from Pfizer (PFE). The stock is up $1.26 to $60.15. Bristol's market capitalization stands around $99B, less than twice that of Pfizer's $200B. A Jefferies analyst last week called Mylan (MYL) the most likely takeover target for Pfizer. Pfizer is "highly motivated" to buy a foreign company using its overseas cash and Mylan looks like the most likely target, Jefferies analyst Jeffrey Holford wrote.
09:56 EDTPFERumor: Bristol-Myers strength attributed to takeover speculation
Subscribe for More Information
06:04 EDTGSKGSK won't pursue divestment of certain brands in established products portfolio
As announced at the company’s Q2 results in July, GSK started a process to consider the divestment of certain North American and European brands in its Established Products Portfolio.The company has evaluated all bids received and has concluded, consistent with its key criteria of maximizing shareholder value, not to pursue divestment of these products.
December 4, 2014
14:49 EDTSHPGSalix, Shire rise after analyst says merger would be 'attractive'
Subscribe for More Information
13:26 EDTAMGNAmgen to host investor meeting
Investor meeting to be held in conjunction with the American Society of Hematology's 56t Annual Meeting in San Francisco on December 8 at 3 pm. Webcast Link
11:12 EDTSNYSanofi diabetes sales head left company, Bloomberg says
Subscribe for More Information
08:45 EDTPFE, BAYRYAbbVie price target raised to $80 from $72 at Jefferies
Jefferies raised its price target for AbbVie shares to $80 while calling the company one of its top five global pharma picks for 2015. The firm's top U.S. pick is Pfizer (PFE) and its top Europe pick is Novartis (NVS). Bayer (BAYRY) and AstraZeneca (AZN) round out the top five. Jefferies thinks AbbVie's "strong momentum" will continue into the first half of 2015 and keeps a Buy rating on the name.
December 3, 2014
19:11 EDTSHPGAstraZeneca, Shire interested in Ariad, Daily Mail reports
Ariad (ARIA) is trading higher on speculation that both AstraZeneca (AZN) and Shire (SHPG) are interested in the company with the possibility of an ensuing auction, according to the Daily Mail, which added that analysts see an acquisition price for Ariad of more than $20 per share. Reference Link
17:33 EDTGSKGSK to shed U.S. jobs as Advair sales slow, Reuters says
GlaxoSmithKline confirmed U.S. job reductions saying "several hundred" commercial and research positions will be eliminated as the company consolidates its operations after the company's Advair sales slowed, says Reuters. Reference Link
17:12 EDTPFEPfizer reports positive results from PROFILE 1014 study
Subscribe for More Information
16:42 EDTPFEDiplomat chosen as limited-distribution pharmacy partner by Pfizer
Subscribe for More Information
16:05 EDTGSKArray BioPharma to regain worldwide rights to Binimetinib
Subscribe for More Information
15:51 EDTAMGNAmgen confirms FDA approval for BLINCYTO
Amgen announced that the FDA has granted approval of BLINCYTO for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. This indication is approved under accelerated approval. Continued approval for this indication may be contingent upon verification of clinical benefit in subsequent trials. With this approval, BLINCYTO becomes the first FDA-approved bispecific CD19-directed CD3 T-cell engager antibody construct product, and the first single-agent immunotherapy to be approved for the treatment of patients with Ph- relapsed or refractory B-cell precursor ALL, the company said. BLINCYTO has a BOXED WARNING in its product label regarding Cytokine Release Syndrome and Neurological Toxicities.
15:32 EDTSNYSanofi whistleblower suit filed over alleged kickbacks, CNBC reports
Subscribe for More Information
13:17 EDTGLWCorning raises quarterly dividend 20%, announces $1.5B share repurchase plan
Subscribe for More Information
13:15 EDTGLWCorning raises quarterly dividend 20%, announces $1.5B share repurchase plan
Subscribe for More Information
13:13 EDTAMGNAmgen drug for rare form of ALL approved by FDA
The FDA said it approved Blincyto to treat patients with Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia, an uncommon form of ALL. Blincyto carries a boxed warning alerting patients and health care professionals that some clinical trial participants had problems with low blood pressure and difficulty breathing at the start of the first treatment, or other side effects in the nervous system. The FDA approved Blincyto with a Risk Evaluation and Mitigation Strategy, which consists of a communication plan to inform health care providers about the serious risks and the potential for preparation and administration errors. Blincyto is marketed by Amgen.
08:11 EDTSNYSanofi says Lemtrada now available in U.S. two weeks post approval
Subscribe for More Information
07:16 EDTPFEFood & Drug Law Institute to hold a conference
Subscribe for More Information
07:05 EDTBIIBBiogen to present data from hematology programs at ASH meeting
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use